Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.
about
Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.Maintaining fluoroquinolone class efficacy: review of influencing factors.Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in CanadaPrevalence and characterization of invasive isolates of Streptococcus pyogenes with reduced susceptibility to fluoroquinolonesHigh genetic diversity of ciprofloxacin-nonsusceptible isolates of Streptococcus pneumoniae in Poland.Stability of fluoroquinolone resistance in Streptococcus pneumoniae clinical isolates and laboratory-derived mutants.Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniaeFluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.High-level fluoroquinolone resistance in Pseudomonas aeruginosa due to interplay of the MexAB-OprM efflux pump and the DNA gyrase mutation.Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in JapanMechanism of action of and resistance to quinolones.Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridgeGenetic relatedness of levofloxacin-nonsusceptible Streptococcus pneumoniae isolates from North America.Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models.Deoxynybomycins inhibit mutant DNA gyrase and rescue mice infected with fluoroquinolone-resistant bacteriaMolecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolonesIn vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinoloneTreating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?A unified anti-mutant dosing strategy.Genomic characterization of ciprofloxacin resistance in a laboratory-derived mutant and a clinical isolate of Streptococcus pneumoniae.Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.Quinolones: action and resistance updated.Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniaePrevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000.Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniaeEvidence of active efflux in resistance to ciprofloxacin and to ethidium bromide by Mycoplasma hominis.Accumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae.gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.PCR-oligonucleotide ligation assay for detection of point mutations associated with quinolone resistance in Streptococcus pneumoniae.High-efficiency generation of antibiotic-resistant strains of Streptococcus pneumoniae by PCR and transformation.Fluoroquinolone resistance in Streptococcus dysgalactiae subsp. equisimilis and evidence for a shared global gene pool with Streptococcus pyogenes.In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanismsRapid screening of fluoroquinolone resistance determinants in Streptococcus pneumoniae by PCR-restriction fragment length polymorphism and single-strand conformational polymorphism.Fluoroquinolone resistance in atypical pneumococci and oral streptococci: evidence of horizontal gene transfer of fluoroquinolone resistance determinants from Streptococcus pneumoniae.
P2860
Q24815187-E60B9BD2-E1B8-4796-8BCA-C10AA3E53EF3Q30310427-FCD13709-F8E8-43AC-A62B-A88D1AA3EB6EQ33663032-9B58C66C-FFDA-468C-A1F1-46FE296D755AQ33770139-FF2556CB-DF09-4A32-9AF0-C01D215A88DAQ33770218-BFADCE9A-3A02-4C99-8AF5-998EF4FFFD8DQ33807463-27B082BF-3FB1-41B6-B2A7-DF0D0B832B4EQ33982417-07858E4F-08DD-4762-9A5B-1752482C0DD3Q34113933-47FD8053-7BE6-4E15-8C6C-0AF3B7E0432EQ34142299-C9E13BA0-C0C2-47F3-896E-C99119BB52B9Q34144100-C0D00B80-0485-4FD9-A309-40B9FC421D90Q34408434-BEB5BEF9-65C4-4461-8AF0-7A2CD787466FQ34502866-318C8755-F7DD-4792-9618-CEC0FE73D4B0Q34597404-329A7049-2153-4EF7-AEC1-1E10CEFEC4D7Q35026714-681709BA-AFEC-4ADB-BDCD-FA1E6569CD52Q35139545-E009A1FB-D5EC-4419-9CDD-5AB2F07978A5Q35201049-9A891C07-ED8D-449F-ACDC-4595FFB0C2A4Q35574888-3475AD9F-9700-4F6B-8D0C-FD7D563268A8Q35635780-AAD0D5D8-31E3-49AC-9E80-70FFDA81144CQ36047665-BF393A1B-7D7D-4399-B1D2-4E7280033304Q36422607-14F31C54-CA2E-4288-A361-2ABDAAB5A3A0Q36728602-1A955DC1-432C-4993-A65E-3150BED7C943Q37188136-B339352B-4450-4E64-8D41-C2795867432BQ37263914-2CCC4448-5DD0-411F-B671-269EDD1ACC09Q37488687-9EBD6E58-7FA6-4CCD-9669-43FF61149DDDQ37488975-4AEDE047-B5A4-4F49-8CE6-591B52058192Q37568953-3CDF36CC-3EBC-4436-B89F-8E505E574722Q37595559-695CA503-2A13-4A05-8A68-B79D527C668FQ37733449-3B4CA0AD-E21C-4027-84DF-4BCA94BB7ABCQ39478343-56D02326-C618-42F0-9A57-58A1C1471EB3Q39651028-D4A6E82E-B2E0-487F-AFC3-F49652052B24Q39652363-F2B25178-767A-4532-9137-11EF2CF719ECQ39653033-B14F4C8D-2B50-40AC-A664-081FD5CDDB75Q39653038-1DAD7AD7-B526-4C30-8020-63E368A62AB7Q39657922-415737C5-6198-4F2C-A8EC-B979E1724D54Q39743304-5D4263E7-A972-4ADF-9413-ED0D57795802Q39743528-C9C3AAF8-2E4D-47C2-963D-4D64525AE812Q40334880-E5237507-9448-4E7D-8BD1-288BAEF9BE20Q41840910-BFEB4766-B524-42BF-9631-51BBFC685215Q42041266-77DDDB8E-0A2D-472D-8843-5FDAB98E3F16Q42112160-91552887-E67C-40AC-8F33-26A405189FDB
P2860
Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Fluoroquinolone resistance in ...... fflux to levels of resistance.
@ast
Fluoroquinolone resistance in ...... fflux to levels of resistance.
@en
type
label
Fluoroquinolone resistance in ...... fflux to levels of resistance.
@ast
Fluoroquinolone resistance in ...... fflux to levels of resistance.
@en
prefLabel
Fluoroquinolone resistance in ...... fflux to levels of resistance.
@ast
Fluoroquinolone resistance in ...... fflux to levels of resistance.
@en
P2093
P2860
P1476
Fluoroquinolone resistance in ...... fflux to levels of resistance.
@en
P2093
Davidson RJ
Mandell LA
de Azavedo JC
P2860
P304
P356
10.1128/AAC.44.11.3049-3054.2000
P407
P577
2000-11-01T00:00:00Z